Hyloris Pharmaceuticals (HYL) H2 2024 earnings summary

Executive summary

• Total revenue and other operating income rose to over €10 million in 2024, up 138% year-over-year, driven by a 305% increase in royalties and milestones.

• Net loss decreased by 59% to €6.3 million, the lowest since IPO.

• R&D progress included NDA submission for Valacyclovir Oral Suspension and successful Dofetilide IV pivotal trial.

• Maxigesic® IV launched in the U.S., with a CMS reimbursement code and a $2.1 million milestone payment.

• Pipeline expanded with four new product candidates, targeting 30 assets by end of 2025.

Financial highlights

• Revenue: €8.5 million (+305% year-over-year); total revenue and other income: €10.0 million (+138%).

• Operating expenses: €16.9 million (down 16%); R&D expenses: €10.3 million (down 29%).

• Operating loss (EBIT): €7.1 million (improved from €16.0 million); net loss: €6.3 million (improved from €15.4 million).

• Cash and cash equivalents: €23.6 million at year-end, down from €30.4 million.

• Equity: €32.1 million at year-end.

Outlook and guidance

• Up to 9 product submissions expected by end of 2026, including Valacyclovir oral liquid (ex-U.S.), Dofetilide IV (U.S.), Atomoxetine oral liquid, and others.

• Targeting 30 product candidates by end of 2025, with accelerated pipeline growth anticipated.

• Exploring licensing and commercial strategies for U.S. cardiovascular portfolio; decision expected in 2025.

• Sufficiently capitalized for current R&D, but additional funding may be needed for U.S. cardiology commercialization.